Cargando…

Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

The pharmaceutical industry’s development of therapeutic medications for the treatment of Parkinson’s disease (PD) endures, as a result of the continuing need for better agents, and the increased clinical demand due to the aging population. Each new drug offers advantages and disadvantages to patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiandaca, Massimo S., Bankiewicz, Krystof S., Federoff, Howard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763661/ https://www.ncbi.nlm.nih.gov/pubmed/24281662 http://dx.doi.org/10.3390/ph5060553

Ejemplares similares

The Use of Convection-Enhanced Delivery with Liposomal Toxins in Neurooncology
por: Fiandaca, Massimo S., et al.
Publicado: (2011)

Evaluation of an AAV2-Based Rapamycin-Regulated Glial Cell Line-Derived Neurotrophic Factor (GDNF) Expression Vector System
por: Hadaczek, Piotr, et al.
Publicado: (2011)

An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function
por: Van Laar, Amber D., et al.
Publicado: (2021)

Fetal Bovine Serum-Derived Extracellular Vesicles Persist within Vesicle-Depleted Culture Media
por: Lehrich, Brandon M., et al.
Publicado: (2018)

Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
por: Ciesielska, Agnieszka, et al.
Publicado: (2017)

Carbidopa-Based Modulation of the Functional Effect of the AAV2-hAADC Gene Therapy in 6-OHDA Lesioned Rats
por: Ciesielska, Agnieszka, et al.
Publicado: (2015)

Potential Metabolomic Linkage in Blood between Parkinson’s Disease and Traumatic Brain Injury
por: Fiandaca, Massimo S., et al.
Publicado: (2018)

Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease
por: Richardson, R Mark, et al.
Publicado: (2020)

Plasma microRNA markers of upper limb recovery following human stroke
por: Edwardson, Matthew A., et al.
Publicado: (2018)

Author Correction: Plasma microRNA markers of upper limb recovery following human stroke
por: Edwardson, Matthew A., et al.
Publicado: (2020)

Merging DBS with viral vector or stem cell implantation: “hybrid” stereotactic surgery as an evolution in the surgical treatment of Parkinson’s disease
por: Rowland, Nathan C, et al.
Publicado: (2016)

Systems healthcare: a holistic paradigm for tomorrow
por: Fiandaca, Massimo S., et al.
Publicado: (2017)

GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
por: Barker, Roger A., et al.
Publicado: (2020)

Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease
por: Christine, Chadwick W., et al.
Publicado: (2019)

Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
por: Nutt, John G., et al.
Publicado: (2020)

Immune Responses in Parkinson's Disease: Interplay between Central and Peripheral Immune Systems
por: Su, Xiaomin, et al.
Publicado: (2014)

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
por: Subramaniam, Sudhakar R., et al.
Publicado: (2017)

Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls
por: Fiandaca, Massimo S., et al.
Publicado: (2018)

Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial
por: Christine, Chadwick W., et al.
Publicado: (2022)

Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials
por: Merola, Aristide, et al.
Publicado: (2021)

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study
por: Mehta, Khyati Y., et al.
Publicado: (2017)

PET 6-[(18)F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates
por: Eberling, Jamie L., et al.
Publicado: (2008)

Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapy
por: Salegio, Ernesto A., et al.
Publicado: (2014)

Convection-Enhanced Delivery of AAV2-PrPshRNA in Prion-Infected Mice
por: Ahn, Misol, et al.
Publicado: (2014)

Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease
por: Fiandaca, Massimo S., et al.
Publicado: (2015)

Rapid Inverse Planning for Pressure-Driven Drug Infusions in the Brain
por: Rosenbluth, Kathryn H., et al.
Publicado: (2013)

Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease
por: Hiller, Benjamin M., et al.
Publicado: (2022)

Should we expand the indications for varicocele treatment?
por: Vakalopoulos, Ioannis, et al.
Publicado: (2017)

Considering the Need to Expand the Indications for Wearable Defibrillator Therapy
Publicado: (2019)

Ultrasound-Enhanced Drug Transport and Distribution in the Brain
por: Liu, Ying, et al.
Publicado: (2010)

Axonal transport of AAV9 in nonhuman primate brain
por: Green, Foad, et al.
Publicado: (2016)

PGC−1α Promoter Methylation in Parkinson’s Disease
por: Su, Xiaomin, et al.
Publicado: (2015)

The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease
por: Miao, Zhijun, et al.
Publicado: (2021)

Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease
por: Markovic, Milica, et al.
Publicado: (2022)

ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN
por: Sebastian, Waldy San, et al.
Publicado: (2013)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
por: Macciardi, Fabio, et al.
Publicado: (2022)

Expanding causal genes for Parkinson’s disease via multi-omics analysis
por: Gu, Xiao-Jing, et al.
Publicado: (2023)

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
por: Polissidis, Alexia, et al.
Publicado: (2020)

Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jsd2hc1kf53dflebdmjg3pudih